FluoSphera, a biotechnology company, has announced the receipt of a CHF 1.1 million grant from Innosuisse, the Swiss Innovation Agency. Teaming up with the renowned EPFL and the University of Geneva, FluoSphera's disruptive innovation project aims to revolutionize in-vitro solutions for drug discovery. The collaboration aims to develop innovative assays for improved drug efficacy and safety predic
Cellestia is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD)
DIAMOND-1 Phase 3 trial, assessing efficacy and safety of OCS-01 eye drops in Diabetic Macular Edema (DME) patients, was initiated as planned. Second Phase 3 trial, DIAMOND-2, anticipated to start in Q1 2024 Stage 1 results showed superiority of OCS-01 eye drops vs. vehicle with robust statistical significance with no unexpected adverse events observed If approved, OCS-01 has the potential to be
GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, today announces the funding of its lead program in Alzheimer’s disease by the Alzheimer’s Drug Discovery Foundation (ADDF), a non-profit organization dedicated to accelerating drug discovery and development in Alzheimer’s disease.